Cardiff University has announced Professor Kathy Triantafilou, from its School of Medicine, is one of five academics worldwide selected to take part in the Immunology Network, a new collaborative immunology research programme run by GSK.

As a member of the Immunology Catalyst sabbatical programme, Kathy Triantafilou has joined GSK’s R&D organisation in Stevenage, where she is working for the next three years alongside GSK scientists. She receives research funds, post-doctoral support and is actively supported in setting up collaborations with the GSK R&D organisation. At the end of her three year sabbatical she will receive a grant to help her return to academia.

Kathy Triantafilou’s work focuses on the molecular mechanisms of inflammation, which is the body’s natural protective response to any injury, infection or irritation. However, if uncontrolled inflammation can cause damage as seen in several inflammatory diseases such as rheumatoid arthritis, osteoarthritis and Alzheimer’s disease. The research will explore the role of sensors of the innate immune system in inflammatory conditions.

Kathy Triantafilou said “This is an exciting time for me. The Immunology Catalyst provides me with the support and freedom to work on ‘blue-sky’ projects while also giving me the chance to learn about the decision-making processes behind the development of new technology: for example, how research translates into a marketable product. This insight is a valuable career mentorship for me. Furthermore, I have established a robust research relationship between GSK and Cardiff University which will foster increased publications as well as increased opportunities for collaborative scientific research.”

Kathy Triantafilou’s expertise aligns well with drug discovery research at GSK. The company has identified immunology as a key area of focus in seeking to advance drug targets for respiratory disease, immuno-inflammation, infectious disease, oncology and vaccines.

Paul-Peter Tak, GSK Research and Development, Senior Vice President of the Immunology Network, said “The Immunology Network will give us access to the brightest scientists in the world who are free in their thinking and who can go into paths that we’ve not thought of yet. We want to make sure that they are connected to the scientists that discover and develop medicines at GSK.”